Luqa Pharmaceuticals announces first launches in Hong Kong S.A.R.

Luqa Pharmaceuticals announces first launches in Hong Kong S.A.R.

Hong Kong SAR – June 1st Company, announces the commencement of commercial operations in Hong Kong S.A.R. through the launch of its innovative portfolio of topical solutions aimed at the dermatology and aesthetics market; and supportive care solutions aimed at improving the quality of life and outcomes for patients undergoing radiotherapy and chemotherapy.

"2013 was a milestone year for us, as we launched Strataderm®, our first commercial product in China. We now want to expand our innovative and quality of life solutions to other parts of Greater China" stated Robert J. Braithwaite, Chairman and Chief Executive Officer of Luqa. "We are excited by the enthusiastic reception we have had so far from physycians in Hong Kong about our portfolio of innovative products. We have been working closely to understand the needs of the Hong Kong market. The feedback received from the medical community makes us confident that we will be able to fulfil our mission of bringing innovative treatment options which will improve the quality of life of patients."

Following the launch of commercial operations in China in February 2013 with the succesful roll out of Strataderm®, Luqa is launching an additional three more products in Mainland China this year. Luqa will expand its portfolio in the dermatology and medical aesthetics field; and will establish its initial presence in the pediatric / gastroenterology field.

About Luqa

Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty care segments in China. Please visit us at, 2014 Luqa Pharmaceuticals ("Luqa"), the China specialty pharmaceutical

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.